Date | Title | Description | |
---|---|---|---|
08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |
11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
11 May 2022 | On Corporate Governance | The Company informs about the appointment of a new member in its Board of Directors | Download |
05 Apr 2022 | Liquidity and counterparty agreements | The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |